{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:15:23Z","timestamp":1745381723114,"version":"3.40.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"DOI":"10.7759\/cureus.82773","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:04:59Z","timestamp":1745323499000},"source":"Crossref","is-referenced-by-count":0,"title":["Compliance With Parathyroid Hormone Analog Medications at a Single Osteoporosis Treatment Center"],"prefix":"10.7759","author":[{"given":"Andrea H","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane C","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Boudani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Chapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin J","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff MS","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022, 33:2049-102. 10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2020 update","volume":"26","author":"Camacho PM","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, et al.. American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2020 update. Endocr Pract. 2020, 26:1-46. 10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020970518","article-title":"Economic burden of osteoporosis-related fractures in the US medicare population","volume":"55","author":"Williams SA","year":"2021","unstructured":"Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR. Economic burden of osteoporosis-related fractures in the US medicare population. Ann Pharmacother. 2021, 55:821-9. 10.1177\/1060028020970518","journal-title":"Ann Pharmacother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer A","year":"2015","unstructured":"Singer A, Exuzides A, Spangler L, et al.. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015, 90:53-62. 10.1016\/j.mayocp.2014.09.011","journal-title":"Mayo Clin Proc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3074","article-title":"Addressing the crisis in the treatment of osteoporosis: a path forward","volume":"32","author":"Khosla S","year":"2017","unstructured":"Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2017, 32:424-30. 10.1002\/jbmr.3074","journal-title":"J Bone Miner Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07070-z","article-title":"Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study","volume":"35","author":"Gold DT","year":"2024","unstructured":"Gold DT, Beckett T, Deal C, et al.. Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study. Osteoporos Int. 2024, 35:1407-15. 10.1007\/s00198-024-07070-z","journal-title":"Osteoporos Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-023-01359-y","article-title":"Healthcare professionals' perspectives and experiences of osteoporosis medication treatment: a qualitative systematic review","volume":"19","author":"Rezae F","year":"2024","unstructured":"Rezae F, Kelly A, Dey S, Moles R, Carter S. Healthcare professionals' perspectives and experiences of osteoporosis medication treatment: a qualitative systematic review. Arch Osteoporos. 2024, 19:8. 10.1007\/s11657-023-01359-y","journal-title":"Arch Osteoporos"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-112","article-title":"Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries","volume":"15","author":"Yun H","year":"2014","unstructured":"Yun H, Curtis JR, Guo L, et al.. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord. 2014, 15:112. 10.1186\/1471-2474-15-112","journal-title":"BMC Musculoskelet Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275020","article-title":"Predictors for self-discontinuation of anti-osteoporosis medication: a hospital-based real-world study","volume":"17","author":"Deng YL","year":"2022","unstructured":"Deng YL, Hsu CS, Hsu CY, et al.. Predictors for self-discontinuation of anti-osteoporosis medication: a hospital-based real-world study. PLoS One. 2022, 17:10.1371\/journal.pone.0275020","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0316-5","article-title":"Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States","volume":"12","author":"Durden E","year":"2017","unstructured":"Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos. 2017, 12:22. 10.1007\/s11657-017-0316-5","journal-title":"Arch Osteoporos"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10457","article-title":"Abaloparatide real-world patient experience study","volume":"5","author":"Gold DT","year":"2021","unstructured":"Gold DT, Weiss R, Beckett T, et al.. Abaloparatide real-world patient experience study. JBMR Plus. 2021, 5:10.1002\/jbm4.10457","journal-title":"JBMR Plus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1055\/a-1062-9447","article-title":"Adherence to teriparatide treatment and risk of fracture: a systematic review and meta-analysis","volume":"51","author":"Chen Q","year":"2019","unstructured":"Chen Q, Guo M, Ma X, Pu Y, Long Y, Xu Y. Adherence to teriparatide treatment and risk of fracture: a systematic review and meta-analysis. Horm Metab Res. 2019, 51:785-91. 10.1055\/a-1062-9447","journal-title":"Horm Metab Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05507-9","article-title":"Persistence and adherence to parenteral osteoporosis therapies: a systematic review","volume":"31","author":"Koller G","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, Ye C. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int. 2020, 31:2093-102. 10.1007\/s00198-020-05507-9","journal-title":"Osteoporos Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4144-7","article-title":"One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study","volume":"28","author":"Reyes C","year":"2017","unstructured":"Reyes C, Tebe C, Martinez-Laguna D, Ali MS, Soria-Castro A, Carbonell C, Prieto-Alhambra D. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int. 2017, 28:2997-3004. 10.1007\/s00198-017-4144-7","journal-title":"Osteoporos Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2023.101730","article-title":"Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications","volume":"20","author":"Hayes KN","year":"2024","unstructured":"Hayes KN, Cadarette SM, Burden AM. Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications. Bone Rep. 2024, 20:10.1016\/j.bonr.2023.101730","journal-title":"Bone Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003633603","article-title":"Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study","volume":"26","author":"Woo C","year":"2010","unstructured":"Woo C, Gao G, Wade S, Hochberg MC. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin. 2010, 26:1003-9. 10.1185\/03007991003633603","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3388-3","article-title":"Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study","volume":"27","author":"Modi A","year":"2016","unstructured":"Modi A, Sen S, Adachi JD, et al.. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int. 2016, 27:1227-38. 10.1007\/s00198-015-3388-3","journal-title":"Osteoporos Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2024.08.003","article-title":"Latest on anabolic agents for osteoporosis treatment","volume":"53","author":"di Filippo L","year":"2024","unstructured":"di Filippo L, Rosen CJ. Latest on anabolic agents for osteoporosis treatment. Endocrinol Metab Clin North Am. 2024, 53:513-23. 10.1016\/j.ecl.2024.08.003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01447-7","article-title":"Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Li M","year":"2024","unstructured":"Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024, 19:89. 10.1007\/s11657-024-01447-7","journal-title":"Arch Osteoporos"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.506870","article-title":"PTH analogues and osteoporotic fractures","volume":"10","author":"Verhaar HJ","year":"2010","unstructured":"Verhaar HJ, Lems WF. PTH analogues and osteoporotic fractures. Expert Opin Biol Ther. 2010, 10:1387-94. 10.1517\/14712598.2010.506870","journal-title":"Expert Opin Biol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.2530","article-title":"Drug prices after patent expirations in high-income countries and implications for cost-effectiveness analyses","volume":"5","author":"Serra-Burriel M","year":"2024","unstructured":"Serra-Burriel M, Martin-Bassols N, Per\u00e9nyi G, Vokinger KN. Drug prices after patent expirations in high-income countries and implications for cost-effectiveness analyses. JAMA Health Forum. 2024, 5:10.1001\/jamahealthforum.2024.2530","journal-title":"JAMA Health Forum"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-018-0406-6","article-title":"The impact of patent expiry on drug prices: a systematic literature review","volume":"16","author":"Vondeling GT","year":"2018","unstructured":"Vondeling GT, Cao Q, Postma MJ, Rozenbaum MH. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018, 16:653-60. 10.1007\/s40258-018-0406-6","journal-title":"Appl Health Econ Health Policy"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3888-9","article-title":"Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States","volume":"28","author":"Burge RT","year":"2017","unstructured":"Burge RT, Disch DP, Gelwicks S, Zhang X, Krege JH. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States. Osteoporos Int. 2017, 28:799-809. 10.1007\/s00198-016-3888-9","journal-title":"Osteoporos Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.17054","article-title":"Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. medicare population","volume":"23","author":"Keshishian A","year":"2017","unstructured":"Keshishian A, Boytsov N, Burge R, et al.. Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. medicare population. J Manag Care Spec Pharm. 2017, 23:1178-90. 10.18553\/jmcp.2017.17054","journal-title":"J Manag Care Spec Pharm"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-018-0487-8","article-title":"Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS)","volume":"13","author":"Sato M","year":"2018","unstructured":"Sato M, Tsujimoto M, Kajimoto K, Uetake H, Shimoda H, Fujiwara S. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS). Arch Osteoporos. 2018, 13:74. 10.1007\/s11657-018-0487-8","journal-title":"Arch Osteoporos"},{"key":"ref26","article-title":"Effectiveness of mobile health platform-based continuity of care in osteoporosis prevention and treatment","volume":"30","author":"Cheng WP","year":"2024","unstructured":"Cheng WP, Sun L, Shen D, Xu GH, Jiang JW, Gu HY. Effectiveness of mobile health platform-based continuity of care in osteoporosis prevention and treatment. Altern Ther Health Med. 2024, 30:144-9.","journal-title":"Altern Ther Health Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-05052-0","article-title":"Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program","volume":"30","author":"van Maren MA","year":"2019","unstructured":"van Maren MA, Wyers CE, Driessen JH, et al.. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporos Int. 2019, 30:1837-44. 10.1007\/s00198-019-05052-0","journal-title":"Osteoporos Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359666-compliance-with-parathyroid-hormone-analog-medications-at-a-single-osteoporosis-treatment-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:04:59Z","timestamp":1745323499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359666-compliance-with-parathyroid-hormone-analog-medications-at-a-single-osteoporosis-treatment-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.82773","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}